Suppr超能文献

基于片段的先导化合物发现:设计先导化合物。

Fragment-based lead discovery: leads by design.

作者信息

Carr Robin A E, Congreve Miles, Murray Christopher W, Rees David C

机构信息

Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, UK.

出版信息

Drug Discov Today. 2005 Jul 15;10(14):987-92. doi: 10.1016/S1359-6446(05)03511-7.

Abstract

Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120-250 Da) compounds are screened relative to HTS campaigns. Fragment-based hits are typically weak inhibitors (10 microM-mM), and therefore need to be screened at higher concentration using very sensitive biophysical detection techniques such as protein crystallography and NMR as the primary screening techniques, rather than bioassays. Compared with HTS hits, these fragments are simpler, less functionalized compounds with correspondingly lower affinity. However, fragment hits typically possess high 'ligand efficiency' (binding affinity per heavy atom) and so are highly suitable for optimization into clinical candidates with good drug-like properties.

摘要

基于片段的先导化合物发现(也称为针状物、形状、结合元件、种子模板或支架)是一种新的先导化合物发现方法,与高通量筛选(HTS)相比,该方法所筛选的化合物分子量要低得多(120 - 250道尔顿)。基于片段的命中物通常是弱抑制剂(10微摩尔 - 毫摩尔),因此需要使用非常灵敏的生物物理检测技术(如蛋白质晶体学和核磁共振)作为主要筛选技术,在更高浓度下进行筛选,而不是采用生物测定法。与高通量筛选的命中物相比,这些片段是更简单、功能化程度更低的化合物,亲和力相应也较低。然而,片段命中物通常具有较高的“配体效率”(每个重原子的结合亲和力),因此非常适合优化成具有良好类药性质的临床候选药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验